TearLab Q1 revenue jumps 486%

Tweet First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 486% to $2.5-million from $422,000 a year ago, and was up 54% sequentially from $1.6-million in the fourth quarter of 2012.  The company reported an adjusted net loss of $0.11 per share, beating consensus analyst estimates by a cent. A total of 388 orders for TearLab [...]

TearLab launches free smartphone IR app

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) announced that its smartphone investor relations application is now available for free download through Apple’s App Store. “The TearLab IR app was designed by Innovasium Digital to provide the investment community with direct and real-time mobile access to company news and information,” TearLab CEO Elias Vamvakas said in a statement. “We [...]

TearLab revenue climbed more than three-fold in Q4

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) posted fourth quarter revenue of $1.6-million, up more than three-fold from $499,000 for the same period in 2011, and an increase of 33% from $1.2-million in the third quarter last year. A total of 232 orders for TearLab systems were booked in the fourth quarter, the company said. Of those, 201 were [...]

TearLab Q3 revenue jumps 264%

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has reported third quarter net revenues of $1.2-million, an increase of 264% from $333,000 for the same period in 2011, and up 69% sequentially from $716,000 in the second quarter this year. “Growing doctor interest in our technology and the significant role that it can play in the objective diagnoses and management [...]

TearLab posts 70% sequential revenue gain in Q2

Tweet Second quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 53% year-over-year to $716,000, climbing 70% sequentially from the first quarter of 2012. The post-CLIA Waiver roll out of the company’s “3/15″ and “3/24″ marketing programs continued to gain momentum in the second quarter, as a total of 128 orders for TearLab Osmolarity systems were booked [...]

TearLab adds reimbursement update section to website

Tweet For Medicare patients, testing with TearLab’s (NASDAQ:TEAR; TSX:TLB) Osmolarity System is reimbursed in every state by CMS.  But, private insurance reimbursement policy is not uniform.  It depends on provider contracts and varies from state to state, payer to payer and even policy to policy. As CEO Elias Vamvakas told investors on TearLab’s quarterly conference [...]

TearLab sees adoption curve rising for osmolarity test

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) is confident that the adoption curve of its groundbreaking TearLab Osmolarity System for the diagnosis of dry eye disease “will steepen significantly in 2012,” says CEO Elias Vamvakas. “In many respects, we just crossed the starting line with the FDA’s issuance of a CLIA waiver at the end of January, 2012,” [...]

TearLab warrants exercised by institutional investors

Tweet Certain institutional shareholders of TearLab (NASDAQ:TEAR; TSX:TLB) have exercised 1,373,700 warrants into an equivalent number of common shares for gross proceeds of about $2.6 million. The warrants were issued in connection with a private placement in June, 2011. Approximately 2,472,454 warrants remain outstanding from the June, 2011, financing. “We would like to thank our [...]

TearLab to explore commercial partnership opportunities in Japan

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has entered into a consulting agreement with one of its directors, Dr. Adrienne Graves, who will oversee identifying and leading discussions with potential partners for the commercialization of the TearLab Osmolarity System in Japan. Dr. Graves has been a member of TearLab’s board since April 2005. She was CEO of Santen [...]

TearLab Osmolarity System gets CLIA Waiver from FDA

Tweet The FDA has granted a waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity System. The FDA took the action after reviewing and accepting labeling submitted to it by TearLab. “We believe that, with CLIA Waiver and Medicare reimbursement in place, and with the updated American [...]

Next Page »